Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report) shares hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $42.58 and last traded at $42.34, with a volume of 2227 shares trading hands. The stock had previously closed at $39.85.
Wall Street Analyst Weigh In
Separately, JPMorgan Chase & Co. started coverage on Ascentage Pharma Group International in a research note on Thursday, March 27th. They issued an "overweight" rating on the stock.
View Our Latest Stock Analysis on Ascentage Pharma Group International
Ascentage Pharma Group International Trading Up 7.5%
The company has a current ratio of 1.26, a quick ratio of 1.26 and a debt-to-equity ratio of 3.24. The business has a fifty day moving average price of $29.29.
Institutional Trading of Ascentage Pharma Group International
An institutional investor recently bought a new position in Ascentage Pharma Group International stock. Monashee Investment Management LLC acquired a new stake in Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Free Report) during the first quarter, according to its most recent filing with the SEC. The firm acquired 159,942 shares of the company's stock, valued at approximately $3,511,000. Monashee Investment Management LLC owned about 0.18% of Ascentage Pharma Group International as of its most recent filing with the SEC.
About Ascentage Pharma Group International
(
Get Free Report)
Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.
See Also
Before you consider Ascentage Pharma Group International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascentage Pharma Group International wasn't on the list.
While Ascentage Pharma Group International currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
